Genprex (GNPX) Change in Receivables (2016 - 2023)
Genprex (GNPX) posted quarterly Change in Receivables of -$34852.0 for Q1 2023, down 208.33% year-over-year from $32171.0 in Q1 2022, and down 200.0% quarter-over-quarter from $34852.0 in Q3 2022.
Genprex (GNPX) Change in Receivables (2016 - 2023) Analysis & Trends
Genprex's Change in Receivables history runs 8 years deep, the most recent figure standing at -$34852.0 for Q1 2023.
- In Q1 2023, Change in Receivables fell 208.33% year-over-year to -$34852.0; the TTM figure through Dec 2023 stood at -$34852.0 (down 200.0% YoY), while the FY2023 annual figure was -$34852.0, down 200.0% from the prior year.
- Change in Receivables for Q1 2023 stood at -$34852.0, down from $34852.0 in the prior quarter.
- The five-year high for Change in Receivables was $34852.0 in Q3 2022, with the low at -$34852.0 in Q1 2023.
- The 5-year median for Change in Receivables is -$42.5 (2020), against an average of -$774.75.
- The sharpest annual moves came in 2019 and 2021: Change in Receivables jumped 1381.74% in 2019, then tumbled 402.38% in 2021.
- Genprex's Change in Receivables stood at $655.0 in 2019, then slumped by 93.59% to $42.0 in 2020, then sank by 402.38% to -$127.0 in 2021, then surged by 27542.52% to $34852.0 in 2022, then slumped by 200.0% to -$34852.0 in 2023.
- Business Quant data shows GNPX's Change in Receivables at -$34852.0 in Q1 2023, $34852.0 in Q3 2022, and -$32171.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -34,852.00 |
| Mar 31, 2023 | -34,852.00 |
| Sep 30, 2022 | 34,852.00 |
| Sep 30, 2022 | 34,852.00 |
| Jun 30, 2022 | -32,171.00 |
| Jun 30, 2022 | -32,171.00 |
| Mar 31, 2022 | 32,171.00 |
| Mar 31, 2022 | 32,171.00 |
| Dec 31, 2021 | -127.00 |
| Dec 31, 2021 | -127.00 |
| Dec 31, 2020 | 42.00 |
| Dec 31, 2020 | 42.00 |
| Jun 30, 2020 | 85.00 |
| Jun 30, 2020 | 85.00 |
| Mar 31, 2020 | -655.00 |
| Mar 31, 2020 | -655.00 |
| Dec 31, 2019 | 655.00 |
| Dec 31, 2019 | 655.00 |
| Sep 30, 2019 | -10,741.00 |
| Sep 30, 2019 | -10,741.00 |